PMEDAP 是人类免疫缺陷病毒 (HIV) 复制的有效抑制剂。PMEDAP 具有抗小鼠巨细胞病毒 (MCMV) 活性。PMEDAP 是莫罗尼鼠肉瘤病毒 (MSV) 诱导的肿瘤形成和相关死亡率的有效抑制剂。
PMEDAP is a potent inhibitor of human immunodeficiency virus (HIV) replication. PMEDAP has anti-murine cytomegalovirus (MCMV) activity. PMEDAP is a very potent inhibitor of Moloney murine sarcoma virus (MSV)-induced tumor formation and associated mortality[1][2].
PMEDAP (0.25-5 mg/kg; IP; daily; starting on the day of MSV-infected and continuing for an additional four days) causes a dose-dependent suppression of tumor formation and mortality in newborn mice inoculated with MSV[1].
[1]. Neyts J, et al. Activity of the anti-HIV agent 9-(2-phosphonyl-methoxyethyl)-2,6-diaminopurine against cytomegalovirus in vitro and in vivo [published correction appears in Eur J Clin Microbiol Infect Dis 1993 Jul;12(7):following 477]. Eur J Clin Microbiol Infect Dis. 1993;12(6):437-446. [2]. Naesens L, et al. 9-(2-Phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP): a novel agent with anti-human immunodeficiency virus activity in vitro and potent anti-Moloney murine sarcoma virus activity in vivo. Eur J Clin Microbiol Infect Dis. 1989;8(12):1043-1047.
动态评分
0.0